多发性硬化视网膜层分割的系统综述与荟萃分析
该系统综述与荟萃分析检索1991年至2016年PubMed、Web of Science和Google Scholar,纳入40篇报告数据(5776只多发性硬化眼和1697只健康对照眼),评估SD-OCT视网膜各层厚度。结果显示视乳头周围RNFL和黄斑GCIPL萎缩最显著且稳健,推荐纳入诊断、监测和研究。
要点
- 视乳头周围RNFL和黄斑GCIPL在多发性硬化眼中萎缩最显著且稳健。
核心结论
- 多发性硬化眼与对照眼最大且最稳健的差异见于视乳头周围RNFL和黄斑GCIPL。
- 炎症疾病活动可能由INL捕捉。
- 因一致性、稳健性和大效应量,推荐将视乳头周围RNFL和黄斑GCIPL纳入诊断、监测和研究。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web of Science和Google Scholar(1991年11月22日至2016年4月19日)。
- 数据来自横断面队列和纵向研究的一个时间点(视神经炎研究至少发病后3个月)。
- 眼数据分类为健康对照、多发性硬化相关视神经炎(MSON)和无视神经炎的多发性硬化(MSNON)。
- 通过随机效应荟萃分析评估各视网膜层分割性能,比较MSON vs 对照、MSNON vs 对照、MSNON vs MSON。
- 最终40篇文章报告数据,共5776只多发性硬化眼(1667只MSON眼和4109只MSNON眼)和1697只健康对照眼。
临床怎么用
- 推荐将视乳头周围RNFL和黄斑GCIPL用于多发性硬化的诊断、监测和研究。
- INL增厚可能提示炎症疾病活动,可作为潜在观察指标。
局限性
- 仅纳入符合已发表OCT质量控制标准的研究,可能排除部分数据。
- 数据来自横断面队列和纵向研究的一个时间点,不能完全反映动态变化。
- 未报告 funding,可能存在资助偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Structural retinal imaging biomarkers are important for early recognition and monitoring of inflammation and neurodegeneration in multiple sclerosis. With the introduction of spectral domain optical coherence tomography (SD-OCT), supervised automated segmentation of individual retinal layers is possible. We aimed to investigate which retinal layers show atrophy associated with neurodegeneration in multiple sclerosis when measured with SD-OCT. METHODS: In this systematic review and meta-analysis, we searched for studies in which SD-OCT was used to look at the retina in people with multiple sclerosis with or without optic neuritis in PubMed, Web of Science, and Google Scholar between Nov 22, 1991, and April 19, 2016. Data were taken from cross-sectional cohorts and from one timepoint from longitudinal studies (at least 3 months after onset in studies of optic neuritis). We classified data on eyes into healthy controls, multiple-sclerosis-associated optic neuritis (MSON), and multiple sclerosis without optic neuritis (MSNON). We assessed thickness of the retinal layers and we rated individual layer segmentation performance by random effects meta-analysis for MSON eyes versus control eyes, MSNON eyes versus control eyes, and MSNON eyes versus MSON eyes. We excluded relevant sources of bias by funnel plots. FINDINGS: Of 25 497 records identified, 110 articles were eligible and 40 reported data (in total 5776 eyes from patients with multiple sclerosis [1667 MSON eyes and 4109 MSNON eyes] and 1697 eyes from healthy controls) that met published OCT quality control criteria and were suitable for meta-analysis. Compared with control eyes, the peripapillary retinal nerve fibre layer (RNFL) showed thinning in MSON eyes (mean difference -20·10 μm, 95% CI -22·76 to -17·44; p<0·0001) and in MSNON eyes (-7·41 μm, -8·98 to -5·83; p<0·0001). The macula showed RNFL thinning of -6·18 μm (-8·07 to -4·28; p<0·0001) in MSON eyes and -2·15 μm (-3·15 to -1·15; p<0·0001) in MSNON eyes compared with control eyes. Atrophy of the macular ganglion cell layer and inner plexiform layer (GCIPL) was -16·42 μm (-19·23 to -13·60; p<0·0001) for MSON eyes and -6·31 μm (-7·75 to -4·87; p<0·0001) for MSNON eyes compared with control eyes. A small degree of inner nuclear layer (INL) thickening occurred in MSON eyes compared with control eyes (0·77 μm, 0·25 to 1·28; p=0·003). We found no statistical difference in the thickness of the combined outer nuclear layer and outer plexiform layer when we compared MSNON or MSON eyes with control eyes, but we found a small degree of thickening of the combined layer when we compared MSON eyes with MSNON eyes (1·21 μm, 0·24 to 2·19; p=0·01). INTERPRETATION: The largest and most robust differences between the eyes of people with multiple sclerosis and control eyes were found in the peripapillary RNFL and macular GCIPL. Inflammatory disease activity might be captured by the INL. Because of the consistency, robustness, and large effect size, we recommend inclusion of the peripapillary RNFL and macular GCIPL for diagnosis, monitoring, and research. FUNDING: None.
引用
- Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017. PMID: 28920886. doi:10.1016/S1474-4422(17)30278-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。